US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Telomir Pharmaceuticals

1.87

-0.0900-4.59%

Pre-market: 1.82-0.0500-2.67%07:26 EDT

Volume:600.50K

Turnover:1.17M

Market Cap:57.71M

PE:-4.51

High:2.00

Open:1.94

Low:1.86

Close:1.96

Loading ...

Overview Company News Filings

Telomir Pharmaceuticals Obtains $3 Million in Straight Equity Sale

MT Newswires Live

Telomir Pharmaceuticals announces $3M in equity financing

Telomir Pharmaceuticals Secures $3M Equity Financing Boost

Telomir Pharmaceuticals Secures $3M Through Equity Sale at Premium, Following Prior $1M Investment

Telomir Pharmaceuticals Unveils Promising Antimicrobial Drug Candidate

Telomir Pharmaceuticals Says Telomir-1 Reduces Tumor Size in Prostate Cancer Animal Model

MT Newswires Live

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

ACCESS Newswire

TELO Study Shows Cancer-Related Breakthrough

Zacks Small Cap Research

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

ACCESS Newswire

Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications

MT Newswires Live

Telomir says captured, stabilized silver in biologically compatible form

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

ACCESS Newswire

TELO Announces Breakthrough

Zacks Small Cap Research

Telomir Pharmaceuticals, Inc. (TELO) Receives a New Rating from Rodman & Renshaw

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

ACCESS Newswire

TELO Again Announces Breakthrough Results

Zacks Small Cap Research

Telomir Pharmaceuticals files $150M mixed securities shelf

TELO Improves Balance Sheet

Zacks Small Cap Research

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TELO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TELO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TELO\",,,,,undefined,":{"symbol":"TELO","market":"US","secType":"STK","nameCN":"Telomir Pharmaceuticals","latestPrice":1.87,"timestamp":1753992000000,"preClose":1.96,"halted":0,"volume":600495,"hourTrading":{"tag":"盘前","latestPrice":1.82,"preClose":1.87,"latestTime":"07:26 EDT","volume":915,"amount":1634.0998725,"timestamp":1754047605143},"delay":0,"floatShares":18718246,"shares":30862671,"eps":-0.414741,"marketStatus":"Pre-Mkt","change":-0.09,"latestTime":"08-01 07:38:44 EDT","open":1.935,"high":2,"low":1.86,"amount":1165506.75045,"amplitude":0.071429,"askPrice":2,"askSize":105,"bidPrice":1.82,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.414741,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1754055000000},"marketStatusCode":1,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":1.87,"preHourTrading":{"tag":"盘前","latestPrice":1.82,"preClose":1.87,"latestTime":"07:26 EDT","volume":915,"amount":1634.0998725,"timestamp":1754047605143},"postHourTrading":{"tag":"盘后","latestPrice":1.78,"preClose":1.87,"latestTime":"19:59 EDT","volume":24980,"amount":45542.3897,"timestamp":1754006349550},"volumeRatio":0.44180051870429454},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TELO\",,,,,undefined,":{"symbol":"TELO","floatShares":18718246,"roa":"-391.62%","roe":"-872.57%","lyrEps":-0.559686,"volumeRatio":0.44180051870429454,"shares":30862671,"dividePrice":0,"high":2,"amplitude":0.071429,"preClose":1.96,"low":1.86,"week52Low":1.12,"pbRate":"-358.23","week52High":8.4,"institutionHeld":0,"latestPrice":1.87,"committee":-0.02439,"eps":-0.414741,"divideRate":0,"volume":600495,"delay":0,"ttmEps":-0.414741,"open":1.935,"prevYearClose":4.12,"prevWeekClose":2.19,"prevMonthClose":1.87,"prevQuarterClose":1.25,"fiveDayClose":2.29,"twentyDayClose":1.18,"sixtyDayClose":2.57},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TELO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537939154","title":"Telomir Pharmaceuticals Obtains $3 Million in Straight Equity Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2537939154","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537939154?lang=en_us&edition=fundamental","pubTime":"2025-05-21 22:07","pubTimestamp":1747836462,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals  said Wednesday it has obtained $3 million in equity financing through a direct investment from its largest shareholder The Bayshore Trust.The deal, which involved the purchase of 1 million Telomir restricted shares at $3 apiece, was structured as a straight stock transaction with no warrants, discounts, and convertible features, the company said.Telomir said the investment will fund its upcoming submission of its investigational new drug application for a rare disease indication.Shares of the company fell 3.1% in recent trading.Price: 2.22, Change: -0.07, Percent Change: -3.10","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4588","EQR","TELO","BK4585","BK4215"],"gpt_icon":0},{"id":"2537239935","title":"Telomir Pharmaceuticals announces $3M in equity financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537239935","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537239935?lang=en_us&edition=fundamental","pubTime":"2025-05-21 21:21","pubTimestamp":1747833670,"startTime":"0","endTime":"0","summary":"Telomir has secured $3M in equity financing, through a direct investment by The Bayshore Trust, the Company’s largest shareholder. The transaction ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/telomir-pharmaceuticals-announces-3m-in-equity-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/telomir-pharmaceuticals-announces-3m-in-equity-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0787776722.HKD","TELO","SG9999002224.SGD","LU1093756168.USD","BK4533","BK4206","LU0683600562.USD","BK4512","LU1894683264.USD","BK4585","BK4588","MMM","BK4534","LU1093756325.SGD","SG9999002232.USD","BK4007","LU1894683348.USD"],"gpt_icon":0},{"id":"2537354269","title":"Telomir Pharmaceuticals Secures $3M Equity Financing Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2537354269","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537354269?lang=en_us&edition=fundamental","pubTime":"2025-05-21 21:18","pubTimestamp":1747833497,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals, Inc. ( ($TELO) ) has provided an announcement. On May 19, 2025, Telomir Pharmaceuticals secured $3 million in equity finan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-secures-3m-equity-financing-boost?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-secures-3m-equity-financing-boost?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4512","BK4206","LU0787776722.HKD","BK4533","EQR","LU1093756168.USD","BK4007","LU1894683348.USD","LU0683600562.USD","SG9999002232.USD","SG9999002224.SGD","BK4215","LU1093756325.SGD","BK4588","BK4585","TELO","LU1894683264.USD","BK4534","MMM"],"gpt_icon":0},{"id":"2537933802","title":"Telomir Pharmaceuticals Secures $3M Through Equity Sale at Premium, Following Prior $1M Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2537933802","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537933802?lang=en_us&edition=fundamental","pubTime":"2025-05-21 20:46","pubTimestamp":1747831571,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has completed a $3 million equity financing through a direct investment by The Bayshore Trust, issuing 1 million restricted shares at $3.00 per share, an 18% premium to the closing price on May 19, 2025. Previously, on December 9, 2024, a $1 million equity investment was made by The Starwood Trust, with shares priced at $7.00 each. Both trusts are affiliated with the company's largest shareholder.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2025, and is solely responsible f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDLc1xZXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2535842060","title":"Telomir Pharmaceuticals Unveils Promising Antimicrobial Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535842060","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535842060?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:16","pubTimestamp":1747311390,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Telomir Pharmaceuticals, Inc. ( ($TELO) ). On May 15, 2025, Telomir Pharmaceuticals announced the identificatio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-unveils-promising-antimicrobial-drug-candidate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-unveils-promising-antimicrobial-drug-candidate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2520338751","title":"Telomir Pharmaceuticals Says Telomir-1 Reduces Tumor Size in Prostate Cancer Animal Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2520338751","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520338751?lang=en_us&edition=fundamental","pubTime":"2025-03-19 21:31","pubTimestamp":1742391082,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals  said Wednesday that preclinical findings showed that Telomir-1 reduces tumor size by 50% in a prostate cancer animal model using \"highly aggressive\" human prostate cancer cells.Telomir-1 \"actively suppresses cancer growth rather than promoting it, and protects against chemotherapy-induced toxicity and mortality when combined with Paclitaxel,\" a chemotherapy drug that is often linked with severe toxicity and side effects, the company said.Telomir said it is advancing Telomir-1 in several indications in addition to oncology. Studies are assessing the drug in age-related diseases like age-related macular degeneration and Wilson's disease, the company said.The company said it plans to file an investigational new drug application by the end of the year.Telomir shares were up 4% in recent Wednesday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2520814821","title":"Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2520814821","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520814821?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:00","pubTimestamp":1742385600,"startTime":"0","endTime":"0","summary":"Telomir-1 Inhibits Tumor Growth, Suppresses Cancer Progression, and Neutralizes Chemotherapy Toxicity. MIAMI, FLORIDA / ACCESS Newswire / March 19, 2025 / Telomir Pharmaceuticals, Inc.  , a leader in age-reversal science, today announced groundbreaking preclinical findings demonstrating that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model using highly aggressive human prostate cancer cells. It was found that Telomir-1 actively suppresses cancer growth rather than promoting it, and protects against chemotherapy-induced toxicity and mortality when combined with Paclitaxel-a widely used chemotherapy drug known for its effectiveness in treating various cancers but often associated with severe toxicity and side effects.Telomir-1 alone at both low and high doses reduced tumor growth by approximately 50%.Contrary to concerns that telomere-elongating drugs may promote cancer, Telomir-1 demonstrated the opposite effect-actively suppressing tumor development, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telomir-pharmaceuticals-announces-significant-anti-120000455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0642271901.SGD","LU1852331112.SGD","BK4532","LU0056508442.USD","LU0109392836.USD","LU2360106780.USD","BK4007","BK4543","IE0004445239.USD","LU0081259029.USD","LU2458330169.SGD","LU0127658192.USD","LU2264538146.SGD","BK4534","LU1316542783.SGD","LU1951198990.SGD","LU1803068979.SGD","LU1989764664.SGD","BK4573","BK4614","IE00B5949003.HKD","LU1951200564.SGD","LU0719512351.SGD","LU1064131342.USD","BK4585","BK4512","BK4141","LU1242518857.USD","BK4575","BK4566","LU1303367103.USD","LU1923623000.USD","LU1242518931.SGD","BK4554","LU1988902786.USD","LU0390134368.USD","LU0979878070.USD","BK4612","LU0823421333.USD","BK4605","IE00BMPRXN33.USD","IE00BMPRXR70.SGD","BK4588","LU1880398471.USD","BK4529","LU2098885051.SGD","TELO","LU2054465674.USD","LU0082616367.USD"],"gpt_icon":1},{"id":"2520649134","title":"TELO Study Shows Cancer-Related Breakthrough","url":"https://stock-news.laohu8.com/highlight/detail?id=2520649134","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520649134?lang=en_us&edition=fundamental","pubTime":"2025-03-19 18:08","pubTimestamp":1742378880,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals  is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”It's this extensive experience and record of success, combined with the test results we’ve seen at this stage of the process that makes us get excited about the potential for Telomir-1 and the company that develops it. We urge investors who hav","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telo-study-shows-cancer-related-100800765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2514083034","title":"Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines","url":"https://stock-news.laohu8.com/highlight/detail?id=2514083034","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514083034?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:00","pubTimestamp":1740574800,"startTime":"0","endTime":"0","summary":"New Study Confirms Telomir-1 Also Reverses Oxidative Stress, Preserves Cellular Integrity, and Prevents Cell Death by Protecting Mitochondria-The Cell's Power Source and Gatekeeper of Life and Death. MIAMI, FLORIDA / ACCESS Newswire / February 26, 2025 / Telomir Pharmaceuticals, Inc.  , a leader in age-reversal science, today announced compelling new preclinical findings demonstrating that Telomir-1 fully reverses calcium dysregulation-an often-overlooked yet fundamental driver of cell death, aging, and disease progression-in multiple human cell lines.\". These findings build upon prior research showing that Telomir-1 also fully reverses oxidative stress , reinforcing its potential as a broad-spectrum therapeutic for aging-related diseases. By restoring intracellular calcium balance, reducing oxidative stress, and protecting mitochondrial integrity and functions, Telomir-1 may directly prevent cellular damage at the root cause, addressing the fundamental mechanisms that drive neurodegen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telomir-pharmaceuticals-announces-breakthrough-telomir-130000187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TELO","BK4566","LU0823434740.USD","IE00BMPRXR70.SGD","BK4007","BK4575","LU1951200564.SGD","LU1303367103.USD","LU0979878070.USD","BK4573","IE0009356076.USD","LU2098885051.SGD","BK4532","LU0823434583.USD","LU1242518857.USD","LU1803068979.SGD","LU2264538146.SGD","IE00BMPRXN33.USD","LU1880398471.USD","IE00B5949003.HKD","BK4585","LU1989764664.SGD","LU0719512351.SGD","LU1988902786.USD","LU2054465674.USD","BK4554","BK4543","LU2250418816.HKD","LU1242518931.SGD","LU1852331112.SGD","LU0082616367.USD","LU0081259029.USD","BK4512","BK4534","LU1880398554.USD","BK4605","BK4141","LU0198837287.USD","LU2360106780.USD","LU0889565833.HKD","LU0109392836.USD","LU0823421333.USD","LU0127658192.USD","LU1923623000.USD","LU0390134368.USD","LU1064131342.USD","LU0056508442.USD","LU0823421416.USD","LU1951198990.SGD"],"gpt_icon":1},{"id":"2513474298","title":"Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2513474298","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513474298?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:55","pubTimestamp":1740146138,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals  said Friday it was able to stabilize both Silver and the highly reactive Silver in a biologically compatible form with its Telomir-1 compound.The company said the Telomir-1 compound would help overcome hurdles in silver-based medical applications and open up new possibilities for advanced antimicrobial treatments, wound care, and infection-resistant medical coatings.The silver-based medical treatments market is rapidly growing, with the silver wound dressings segment valued at $1.03 billion in 2024 and expected to reach $1.36 billion by 2030, the company said.Additionally, the company added that the antimicrobial coatings market, which includes silver-infused medical devices, hospital surfaces, and implants, is projected to grow from $11.65 billion in 2024 to $33.7 billion by 2031.Telomir said it is advancing research and development to explore clinical applications of stabilized Silver complexed-Telomir-1 and is evaluating regulatory pathways to bring these in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B7SZL793.SGD","BLZ.SI","IE00B66KJ199.SGD","IE0031619046.USD","TELO","BK4007","COMP.USD.CC","COMP.USD.HKCC","BK4157","BK6522","BK6088","AEIS","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2513393260","title":"Telomir says captured, stabilized silver in biologically compatible form","url":"https://stock-news.laohu8.com/highlight/detail?id=2513393260","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513393260?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:15","pubTimestamp":1740143721,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals (TELO) announced Telomir-1 has captured and stabilized both Silver and the highly reactive Silver in a biologically compati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/telomir-says-captured-stabilized-silver-in-biologically-compatible-form?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/telomir-says-captured-stabilized-silver-in-biologically-compatible-form?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2513606712","title":"Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2513606712","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513606712?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:00","pubTimestamp":1740142800,"startTime":"0","endTime":"0","summary":"MIAMI, FLORIDA / ACCESS Newswire / February 21, 2025 / Telomir Pharmaceuticals, Inc. , or Telomir, a leader in age-reversal science, today announced a breakthrough achievement-Telomir-1 has successfully captured and stabilized both Silver  and the highly reactive Silver  in a biologically compatible form. This milestone overcomes a major limitation in silver-based medical applications, opening the door for advanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings.Silver-based medical treatments represent a rapidly growing market, with the silver wound dressings segment valued at $1.03 billion in 2024 and projected to reach $1.36 billion by 2030  . Additionally, the antimicrobial coatings market-which includes silver-infused medical devices, hospital surfaces, and implants-is expected to grow from $11.65 billion in 2024 to $33.7 billion by 2031, at a CAGR of 14.2%  .Anti-Inflammatory and Immune-Modulating Properties - Silver may reduce excessive i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telomir-pharmaceuticals-achieves-breakthrough-silver-130000887.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2513446291","title":"TELO Announces Breakthrough","url":"https://stock-news.laohu8.com/highlight/detail?id=2513446291","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513446291?lang=en_us&edition=fundamental","pubTime":"2025-02-21 18:08","pubTimestamp":1740132480,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals  is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”The ability to harness the abilities of Silver has an enormous potential impact, including:. Increased Oxidizing Power – Ag is a stronger oxidizing agent than Ag, which could make it more effective at disrupting bacterial cell membranes, proteins, and DNA, potentially leading to enhanced antimicrobial activity.While at the beginning stages of discovery, this development has a large economic potential, with the antimicrobial coatings market expected to grow t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telo-announces-breakthrough-100800310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2513529082","title":"Telomir Pharmaceuticals, Inc. (TELO) Receives a New Rating from Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2513529082","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513529082?lang=en_us&edition=fundamental","pubTime":"2025-02-21 17:15","pubTimestamp":1740129319,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw analyst Elemer Piros initiated coverage with a Buy rating on Telomir Pharmaceuticals, Inc. (TELO – Research Report) yesterday and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/telomir-pharmaceuticals-inc-telo-receives-a-new-rating-from-rodman-renshaw?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/telomir-pharmaceuticals-inc-telo-receives-a-new-rating-from-rodman-renshaw?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TELO"],"gpt_icon":0},{"id":"2512157329","title":"Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2512157329","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512157329?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:00","pubTimestamp":1739883600,"startTime":"0","endTime":"0","summary":"MIAMI, FLORIDA / ACCESS Newswire / February 18, 2025 / Telomir Pharmaceuticals, Inc. , or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent preclinical studies conducted in human retinal cell lines. These studies demonstrated the ability of Telomir-1 to significantly reverse copper and iron-induced elevation of Reactive Oxygen Species .AMD is a leading cause of blindness in adults over 50, affecting millions worldwide. The disease is characterized by the progressive deterioration of the retinal pigment epithelium  and photoreceptor cells, leading to central vision loss. AMD is classified into two forms:. Dry  AMD, the most common form, which is characterized by a gradual loss of RPE and photoreceptors due to oxidative stress and inflammation.Telomir's lead compound, Telomir-1, was developed to neutralize metal-induced oxidative stress-a key driver of AMD progression. In a recently conducted preclinical study using human retinal cell lines","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telomir-pharmaceuticals-announces-significant-reduction-130000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GFS","LU1989764664.SGD","BK4554","LU0823421333.USD","LU0081259029.USD","LU1316542783.SGD","BK4543","LU0823434740.USD","LU1880398471.USD","LU0823421416.USD","IE00BMPRXR70.SGD","LU0889565833.HKD","LU1951200564.SGD","BK4605","BK4529","LU0056508442.USD","LU2098885051.SGD","LU0979878070.USD","BK4007","LU2360106780.USD","IE0004445239.USD","LU2054465674.USD","BK4566","AMD","LU0127658192.USD","LU0082616367.USD","LU1242518857.USD","BK4534","LU2250418816.HKD","LU2458330243.SGD","IE00B5949003.HKD","BK4512","IE0009356076.USD","IE00BMPRXN33.USD","BK4141","LU0719512351.SGD","LU2458330169.SGD","LU1803068979.SGD","LU0198837287.USD","TELO","LU1242518931.SGD","LU1951198990.SGD","LU2264538146.SGD","LU1923623000.USD","BK4575","LU0390134368.USD","LU1880398554.USD","BK4588","BK4532","LU1064131342.USD"],"gpt_icon":1},{"id":"2512164443","title":"TELO Again Announces Breakthrough Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2512164443","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512164443?lang=en_us&edition=fundamental","pubTime":"2025-02-18 18:45","pubTimestamp":1739875500,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals  is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”The company also recently released potential groundbreaking results from a preclinical study of Telomir-1 on human retinal cell lines. Data from the test showed the ability of Telomir-1 to “significantly reverse copper- and iron-induced elevation of Reactive Oxygen Species .”According to the company, there are currently no approved drugs specifically targeting the oxidative stress caused by the bird flu or similar viruses. Telomir-1’s ability to reverse oxid","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telo-again-announces-breakthrough-results-104500500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2360106780.USD","LU0642271901.SGD","LU1303367103.USD","BK4529","BK4605","LU2098885051.SGD","LU0719512351.SGD","LU0979878070.USD","LU1242518857.USD","LU1988902786.USD","LU0127658192.USD","LU1880398471.USD","LU0390134368.USD","LU0823434583.USD","LU2250418816.HKD","LU1852331112.SGD","LU0889565833.HKD","IE0004445239.USD","BK4007","LU0823421333.USD","LU1242518931.SGD","LU1316542783.SGD","LU0056508442.USD","LU0109392836.USD","BK4588","IE0009356076.USD","IE00BMPRXN33.USD","IE00BMPRXR70.SGD","LU0082616367.USD","LU1951198990.SGD","LU1880398554.USD","LU2458330169.SGD","LU1064131342.USD","LU2054465674.USD","LU1951200564.SGD","BK4573","LU0823421416.USD","LU2458330243.SGD","BK4575","BK4141","BK4532","BK4585","IE00B5949003.HKD","TELO","BK4534","BK4543","LU1923623000.USD","LU0198837287.USD","LU0823434740.USD"],"gpt_icon":1},{"id":"2511643307","title":"Telomir Pharmaceuticals files $150M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2511643307","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511643307?lang=en_us&edition=fundamental","pubTime":"2025-02-15 06:05","pubTimestamp":1739570717,"startTime":"0","endTime":"0","summary":"17:02 EST Telomir Pharmaceuticals (TELO) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/telomir-pharmaceuticals-files-150m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/telomir-pharmaceuticals-files-150m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2509341492","title":"TELO Improves Balance Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2509341492","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509341492?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:27","pubTimestamp":1738758420,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals  is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”Company management just released its 2024 annual report that showed the company’s progress in advancing their research, while also showing an improvement in the cash balance from the year ago period—a very positive development for a company at this stage.The company also recently released potential groundbreaking results from a preclinical study of Telomir-1 on human cell lines. Data from the test showed the ability of Telomir-1 to “fully reverse copper-indu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telo-improves-balance-sheet-122700951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","TELO"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TELO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"TELO","fiscalQuarterEnding":"2025/03","expectedEps":-0.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2025-02-04","symbol":"TELO","fiscalQuarterEnding":"2024/12","expectedEps":-0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"post","actualEps":-0.1},{"market":"US","date":"2024-11-12","symbol":"TELO","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TELO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TELO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TELO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TELO","date":"2025-07-31","current":-4.855606,"percent":0.858311,"low":-83.265127,"twenty":-9.904228,"median":-7.039274,"eighty":-5.162852,"high":-2.69963,"avg":-11.553342,"sd":13.901121,"marketCap":60490835},"quantilePoints":[{"date":"2024-02-16","current":-56.39638,"twenty":-61.770129,"median":-49.049457,"eighty":-41.982417,"marketCap":238655100},{"date":"2024-02-23","current":-62.343889,"twenty":-63.029602,"median":-60.594622,"eighty":-46.922348,"marketCap":263823442},{"date":"2024-03-01","current":-63.46342,"twenty":-63.421438,"median":-62.588787,"eighty":-53.457611,"marketCap":268561012},{"date":"2024-03-08","current":-60.874505,"twenty":-63.351467,"median":-62.553802,"eighty":-58.915325,"marketCap":257605381},{"date":"2024-03-15","current":-45.550923,"twenty":-63.197532,"median":-61.749139,"eighty":-48.657621,"marketCap":192759889},{"date":"2024-03-22","current":-47.510102,"twenty":-63.029602,"median":-60.594622,"eighty":-45.928765,"marketCap":201050637},{"date":"2024-03-28","current":-35.580099,"twenty":-62.973626,"median":-56.39638,"eighty":-42.472212,"marketCap":150565904},{"date":"2024-04-05","current":-16.558518,"twenty":-62.833684,"median":-48.559663,"eighty":-36.881554,"marketCap":216450701},{"date":"2024-04-12","current":-18.574281,"twenty":-62.595784,"median":-46.390571,"eighty":-17.881143,"marketCap":242800474},{"date":"2024-04-19","current":-18.007992,"twenty":-62.469837,"median":-45.480952,"eighty":-18.234508,"marketCap":235398021},{"date":"2024-04-26","current":-15.402836,"twenty":-62.287913,"median":-41.632564,"eighty":-16.272973,"marketCap":201343774},{"date":"2024-05-03","current":-15.493668,"twenty":-61.8401,"median":-38.868721,"eighty":-15.530047,"marketCap":202531127},{"date":"2024-05-10","current":-14.814122,"twenty":-61.126399,"median":-34.985348,"eighty":-15.280653,"marketCap":193648183},{"date":"2024-05-17","current":-9.713938,"twenty":-60.762552,"median":-20.205194,"eighty":-14.460757,"marketCap":183044909},{"date":"2024-05-24","current":-9.899514,"twenty":-60.034856,"median":-18.959358,"eighty":-13.282876,"marketCap":186541828},{"date":"2024-05-31","current":-9.506677,"twenty":-58.635442,"median":-18.087272,"eighty":-12.474215,"marketCap":179139374},{"date":"2024-06-07","current":-8.846709,"twenty":-55.220872,"median":-16.988785,"eighty":-10.175947,"marketCap":166703252},{"date":"2024-06-14","current":-8.642433,"twenty":-50.224965,"median":-16.082609,"eighty":-9.764378,"marketCap":162853977},{"date":"2024-06-21","current":-8.249595,"twenty":-49.049457,"median":-15.652229,"eighty":-9.506677,"marketCap":155451523},{"date":"2024-06-28","current":-7.558201,"twenty":-48.069868,"median":-15.505107,"eighty":-8.846709,"marketCap":142423205},{"date":"2024-07-05","current":-6.803952,"twenty":-47.622055,"median":-15.431264,"eighty":-8.793283,"marketCap":128210494},{"date":"2024-07-12","current":-6.489682,"twenty":-46.614477,"median":-14.995334,"eighty":-8.611006,"marketCap":122288531},{"date":"2024-07-19","current":-5.892568,"twenty":-46.222641,"median":-14.134574,"eighty":-8.227596,"marketCap":111036802},{"date":"2024-07-26","current":-6.096844,"twenty":-45.67687,"median":-13.432376,"eighty":-7.822188,"marketCap":114886078},{"date":"2024-08-02","current":-5.248314,"twenty":-45.438969,"median":-12.639572,"eighty":-6.797667,"marketCap":98896778},{"date":"2024-08-09","current":-6.741098,"twenty":-44.067543,"median":-12.367753,"eighty":-6.690814,"marketCap":127026102},{"date":"2024-08-16","current":-6.303607,"twenty":-42.052388,"median":-10.284417,"eighty":-6.64996,"marketCap":118143157},{"date":"2024-08-23","current":-8.29422,"twenty":-40.401079,"median":-9.899514,"eighty":-6.678244,"marketCap":155451523},{"date":"2024-08-30","current":-8.278421,"twenty":-39.141606,"median":-9.736016,"eighty":-6.690814,"marketCap":155155425},{"date":"2024-09-06","current":-8.136234,"twenty":-38.861724,"median":-9.674022,"eighty":-6.712813,"marketCap":152490542},{"date":"2024-09-13","current":-9.589698,"twenty":-36.881554,"median":-9.506677,"eighty":-6.734812,"marketCap":179731570},{"date":"2024-09-20","current":-12.386034,"twenty":-35.223248,"median":-9.49882,"eighty":-6.759954,"marketCap":232140941},{"date":"2024-09-27","current":-10.774586,"twenty":-34.271647,"median":-9.637093,"eighty":-6.791381,"marketCap":201938931},{"date":"2024-10-04","current":-8.578593,"twenty":-25.750182,"median":-9.548188,"eighty":-6.888805,"marketCap":160781290},{"date":"2024-10-11","current":-8.009846,"twenty":-20.168951,"median":-9.479108,"eighty":-7.001943,"marketCap":150121756},{"date":"2024-10-18","current":-7.425301,"twenty":-19.534707,"median":-9.44751,"eighty":-7.071981,"marketCap":139166125},{"date":"2024-10-25","current":-7.01454,"twenty":-19.059025,"median":-9.384317,"eighty":-6.903527,"marketCap":131467574},{"date":"2024-11-01","current":-6.714368,"twenty":-18.728312,"median":-9.226332,"eighty":-6.834437,"marketCap":125841709},{"date":"2024-11-08","current":-6.666973,"twenty":-18.282076,"median":-8.941959,"eighty":-6.759954,"marketCap":124953415},{"date":"2024-11-15","current":-4.809979,"twenty":-18.039704,"median":-8.846709,"eighty":-6.708049,"marketCap":110444606},{"date":"2024-11-22","current":-5.467643,"twenty":-17.654627,"median":-8.799568,"eighty":-6.673736,"marketCap":125545611},{"date":"2024-11-29","current":-5.132363,"twenty":-17.074838,"median":-8.768141,"eighty":-6.632216,"marketCap":117847059},{"date":"2024-12-06","current":-8.407791,"twenty":-16.522185,"median":-8.642433,"eighty":-6.569924,"marketCap":193055987},{"date":"2024-12-13","current":-6.737953,"twenty":-16.313655,"median":-8.594391,"eighty":-6.600602,"marketCap":154713889},{"date":"2024-12-20","current":-6.712037,"twenty":-15.964821,"median":-8.461728,"eighty":-6.495967,"marketCap":154118835},{"date":"2024-12-27","current":-6.310352,"twenty":-15.760957,"median":-8.366804,"eighty":-6.403683,"marketCap":144895507},{"date":"2025-01-03","current":-5.856836,"twenty":-15.652229,"median":-8.303377,"eighty":-6.363974,"marketCap":134482072},{"date":"2025-01-10","current":-5.325574,"twenty":-15.570683,"median":-8.28632,"eighty":-6.315537,"marketCap":122283477},{"date":"2025-01-17","current":-6.077115,"twenty":-15.523297,"median":-8.249595,"eighty":-6.288654,"marketCap":139540026},{"date":"2025-01-24","current":-6.517673,"twenty":-15.50282,"median":-8.139601,"eighty":-6.28436,"marketCap":149655935},{"date":"2025-01-31","current":-6.297394,"twenty":-15.473282,"median":-8.073041,"eighty":-6.236001,"marketCap":144597981},{"date":"2025-02-07","current":-7.867,"twenty":-15.425578,"median":-8.088839,"eighty":-6.236001,"marketCap":130062872},{"date":"2025-02-14","current":-7.722981,"twenty":-15.280653,"median":-8.030693,"eighty":-6.247693,"marketCap":127681858},{"date":"2025-02-21","current":-7.038894,"twenty":-15.117652,"median":-7.97035,"eighty":-6.260979,"marketCap":116372043},{"date":"2025-02-28","current":-7.200915,"twenty":-14.922849,"median":-7.899257,"eighty":-6.280067,"marketCap":119050684},{"date":"2025-03-07","current":-7.830995,"twenty":-14.578546,"median":-7.867,"eighty":-6.294726,"marketCap":129467618},{"date":"2025-03-14","current":-8.245048,"twenty":-14.152696,"median":-7.888185,"eighty":-6.298884,"marketCap":136313033},{"date":"2025-03-21","current":-8.209043,"twenty":-13.908059,"median":-7.867,"eighty":-6.302115,"marketCap":135717779},{"date":"2025-03-28","current":-7.110904,"twenty":-13.595467,"median":-7.836063,"eighty":-6.306305,"marketCap":117562550},{"date":"2025-04-04","current":-5.27467,"twenty":-13.332709,"median":-7.821994,"eighty":-6.280067,"marketCap":87204626},{"date":"2025-04-11","current":-4.842615,"twenty":-12.988406,"median":-7.793903,"eighty":-6.226574,"marketCap":80061584},{"date":"2025-04-17","current":-4.464567,"twenty":-12.673549,"median":-7.741272,"eighty":-6.154861,"marketCap":73811424},{"date":"2025-04-25","current":-4.590583,"twenty":-12.555761,"median":-7.674628,"eighty":-6.056383,"marketCap":75894811},{"date":"2025-05-02","current":-4.662592,"twenty":-12.434833,"median":-7.63297,"eighty":-6.012327,"marketCap":77085317},{"date":"2025-05-09","current":-4.48257,"twenty":-12.382378,"median":-7.614926,"eighty":-5.935607,"marketCap":74109050},{"date":"2025-05-16","current":-5.972632,"twenty":-12.227313,"median":-7.558201,"eighty":-5.893196,"marketCap":74406677},{"date":"2025-05-23","current":-5.255916,"twenty":-11.632708,"median":-7.513523,"eighty":-5.862019,"marketCap":65477876},{"date":"2025-05-30","current":-5.017011,"twenty":-11.501318,"median":-7.475136,"eighty":-5.83092,"marketCap":62501609},{"date":"2025-06-06","current":-4.801996,"twenty":-11.15375,"median":-7.4411,"eighty":-5.738446,"marketCap":59822968},{"date":"2025-06-13","current":-4.778106,"twenty":-10.774586,"median":-7.421122,"eighty":-5.634716,"marketCap":59525342},{"date":"2025-06-20","current":-4.204733,"twenty":-10.62292,"median":-7.416943,"eighty":-5.48096,"marketCap":52382300},{"date":"2025-06-27","current":-4.06139,"twenty":-10.489162,"median":-7.344933,"eighty":-5.438999,"marketCap":50596540},{"date":"2025-07-03","current":-2.747411,"twenty":-10.309584,"median":-7.267316,"eighty":-5.403258,"marketCap":34227071},{"date":"2025-07-11","current":-2.795192,"twenty":-10.167924,"median":-7.19827,"eighty":-5.305212,"marketCap":34822325},{"date":"2025-07-18","current":-2.890754,"twenty":-10.119238,"median":-7.110904,"eighty":-5.252875,"marketCap":36012831},{"date":"2025-07-25","current":-5.470931,"twenty":-9.985876,"median":-7.051517,"eighty":-5.230053,"marketCap":68156516},{"date":"2025-07-31","current":-4.855606,"twenty":-9.904228,"median":-7.039274,"eighty":-5.162852,"marketCap":60490835}],"updateTime":1754042137272}}}